AzTrials
AzTrials

Peripheral Nerve InjuryPhase 4Nerve-RESTORE℠NCT07657182

Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction

A Phase 4 study testing Avance Nerve Graft and Sural nerve autograft in people with Peripheral Nerve Injury and Peripheral Nerve Discontinuity, run by Axogen Corporation at 3 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a multicenter, 1:1 randomized, prospective, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Avance Nerve Graft and Sural nerve autograft
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
178 participants
Where
3 sitesUnited States
Study dates
11 Jun 2026to 5 Dec 2030
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Study Participant Criteria
  • Be ≥ 18 years of age at the time of consent;
  • Willing and able to comply with all aspects of the treatment and evaluation schedule over a 24-month duration;
  • Provide documented Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to initiation of any study procedures;
  • Injury/Repair Criteria for Each Nerve
  • Primary or secondary nerve injury repair with sural nerve autograft or Avance Nerve Graft for fully transected reconstruction of the following upper extremity mixed and/or motor nerve(s):
Show all 17Show fewer
  • Median nerve: proximal nerve stump within 20 cm from the center point of the thenar eminence and distal to the crease of the elbow;
  • Anterior interosseous nerve;
  • Median nerve recurrent motor branch;
  • Radial nerve: proximal nerve stump within 20 cm of the center of the forearm (midpoint between the tip of the olecranon and the styloid process) and distal to the mid-humerus;
  • Posterior interosseous nerve.
  • Zone of injury of eligible nerve(s) resectable to healthy nerve both distally and proximally and within the anatomical regions of Inclusion Criterion #4;
  • In study participants with multiple eligible nerve repairs, repair of all eligible nerves completed with the same study treatment, either Avance Nerve Graft or sural nerve autograft;
  • Measured nerve gap(s) following resection > 25 mm;
  • Nerve(s) repaired ≤ 120 days post injury;
  • Undergo coaptation on both the proximal and distal portion of the nerve gap(s) per the USPI for Avance Nerve Graft and per standard of care for sural nerve autograft; and
  • Either treatment method, Avance Nerve Graft or sural nerve autograft, is a viable option for all eligible nerve repair(s) (i.e., volume of injured nerve[s] does not exceed availability of sural nerve autograft for reconstruction, study participants are not treated with a combination of treatment types).

Who cannot join

  • Study Participant Criteria
  • Currently enrolled in another clinical study that may interfere with treatment, assessment of recovery, or participation in this study;
  • Deformities or injuries of the limb, hand, or digits that affect both the primary and secondary assessments for eligible nerve repair(s);
  • History of neuropathy of any etiology, diabetic neuropathy or any other known neuropathy including compressive/traumatic neuropathies affecting the target limb;
  • History of progressive neurodegenerative or autoimmune disorder affecting peripheral nerve or motor function (e.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease);
  • History of chronic ischemic condition of the upper extremity;
Show all 21Show fewer
  • Expected use of medication during the study that is known to impact nerve regeneration or to cause peripheral neuropathy;
  • Undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular systems;
  • Participant is unlikely to comply with all study requirements and standard medical care procedures for the duration of the study schedule;
  • Injury/Repair Criteria for Each Nerve
  • Median nerve repairs where the ulnar nerve has been transected due to injury or repair;
  • Repair(s) of a sensory-only proximal nerve stump;
  • Incomplete nerve transections;
  • Multilevel nerve injury pattern requiring two or more isolated reconstructions along the nerve pathway (for example, reconstruction of median nerve in forearm and recurrent motor branch resulting in repair pattern of graft to native nerve to graft to distal target);
  • Inadequate soft tissue coverage or extensive soft tissue injury which will impair recovery assessment;
  • Nerve avulsion injuries and nerve traction injuries resulting in rupture of the nerve;
  • Replantation/amputation of the limb, hand, or digits involved in both the primary and secondary assessments for eligible nerve repair(s);
  • Nerve repairs utilizing either end-to-side or side-to-side coaptation techniques;
  • Nerve transfer, tendon transfer, or other concomitant treatment at the time of nerve repair that affects assessment of function of the innervated muscle organ;
  • Use of coaptation devices that include metallic components or activated polymers and coaptations completed with fibrin glue only; and
  • Injuries with vascular damage resulting in inadequate perfusion despite repair (i.e., both radial and ulnar arteries injured [one injured artery is allowed]).

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Stacy Arnold contact

(386) 462-6800

clinicalresearch@axogeninc.com

Hayley Nicolosi contact

(386) 462-6800

hnicolosi@axogeninc.com

United States3 sites, 3 recruiting

  • University of Missouri- Columbia

    Columbia, Missouri, 65121

    Bryce Rizanovic, 636-578-9812, brycefletcher@health.missouri.edu

    Julia Nuelle, MD

    Recruiting

  • OrthoIndy

    Indianapolis, Indiana, 46260

    Melanie Glover, 317-802-2880, mglover@orthoindy.com

    Brandon Smetana, MD

    Recruiting

  • Orlando Health

    Orlando, Florida, 32806

    Nicolette Clouser, (321) 843-5687, nicolette.clouser@orlandohealth.com

    Justin Zumsteg, MD

    Recruiting

Other trials in United States

About this study

Official title: A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction

This is a multicenter, 1:1 randomized, prospective, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24.

Read the detailed description

This is a multicenter, 1:1 randomized, prospective, evaluator blinded, comparative study in participants requiring reconstruction of a mixed or motor nerve in the upper extremity. The study will assess recovery of motor and sensory function via MRCC score for nerve repairs with Avance Nerve Graft (Study Treatment) and sural nerve autograft (Comparator) through non-inferiority analyses. Participants will be considered enrolled to the study once all screening and eligibility criteria have been met and the participant has been centrally randomized to either Avance Nerve Graft or sural nerve autograft; Inclusion and exclusion criteria are defined at decision points for pre-operative screening eligibility and operative eligibility. This study will consist of a screening visit, an operative visit, and 9 post-operative follow-up visits at Week 4, and Months 3, 6, 9, 12, 15, 18, 21, and 24.

Being tested
Avance Nerve Graft, Sural nerve autograft
Keywords
Avance Nerve Graft, Sural Nerve Autograft, Processed Nerve Allograft, Peripheral Nerve Reconstruction, Mixed Nerve Repair, Motor Nerve Repair, MRCC, Nerve Gap, Nerve-RESTORE
Medical subject headings
Peripheral Nerve Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Avance Nerve GraftBiological

    Also called Acellular nerve allograft-arwx

    A commercially available, sterile, single-use peripheral nerve scaffold indicated for the treatment of functional deficits, manufactured from decellularized and sterilized extracellular matrix derived from human peripheral nerve tissue.

  • Sural nerve autograftProcedure or surgery

    A patient's own peripheral nerve tissue harvested in a secondary surgical procedure of the lower extremity where a functioning sural nerve is sacrificed for use in the reconstruction of a nerve defect.

Study groups in NCT07657182
Study groupRoleWhat they receive
Avance Nerve GraftExperimentalStudy Treatment: Avance Nerve Graft repairs of mixed or motor nerves (> 25 mm gaps)
Receives: Biological: Avance Nerve Graft
Sural nerve autograftActive comparatorComparator: Sural nerve autograft repairs of mixed or motor nerves (> 25 mm gaps)
Receives: Procedure: Sural nerve autograft

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recovery of motor function

    Medical Research Council Classification (MRCC) of motor recovery score. This is an ordinal scale from M0-M5, with grade M0 meaning no contraction and M5 meaning full recovery in all muscles.

    Measured: Assessed at 24 months

  2. Recovery of sensory function

    Medical Research Council Classification (MRCC) of sensory recovery score. This is an ordinal scale from S0-S4, with grade S0 meaning absence of sensibility in the autonomous area and S4 meaning complete recovery (2-point discrimination, 2-6 mm).

    Measured: Assessed at 24 months

Secondary outcomes (6)

  1. Meaningful recovery (MR) of motor and sensory function

    Medical Research Council Classification (MRCC) of motor recovery score. Meaningful recovery is defined as ≥ M3 MRCC of motor recovery and ≥ S3 MRCC of sensory recovery.

    Measured: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24

  2. Treatment response (TR) of motor and sensory function

    Medical Research Council Classification (MRCC) of motor recovery score. Treatment response is defined as a 1-point increase in MRCC score from post-operative baseline.

    Measured: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24

  3. Time to MR of motor and sensory function

    Time from surgery to meaningful recovery of motor function in all repairs and of sensory function in mixed nerve repairs.

    Measured: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24

  4. Time to TR of motor and sensory function

    Time from surgery to treatment response of motor function in all repairs and of sensory function in mixed nerve repairs.

    Measured: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24

  5. QuickDASH upper extremity disability score

    The QuickDASH questionnaire (including Work and Sports/Performance Art modules if applicable) is a PROM questionnaire to measure physical functions and symptoms in participants with upper limb musculoskeletal disorders and will be used to assess the study participant's functional quality of life (QoL)as it pertains to the affected arm. This 11-item questionnaire addresses arm-specific symptoms and disability during the preceding week and is used to estimate the participant's view of disability. Each item is based on an ordinal scale from 1 to 5, where higher values are worse. QuickDASH scores range from 0 to 100, with a score of 0 indicating no disability and a score of 100 representing the most severe disability.

    Measured: Assessed at 24 months

  6. Lower Extremity Functional Scale (LEFS) score

    The LEFS is a valid and reliable assessment for documenting function for individuals and groups with injury or disability to the lower extremity. It is based on the World Health Organization's model of disability and handicap and is applicable to a wide variety of participants with lower extremity orthopedic conditions, including participants with a range of disability levels, conditions, diseases, treatments, and ages. Applicable to sural nerve autograft group only. The LEFS consists of 20 questions, with each activity rated from 0 (extremely difficult or unable) to 4 (no difficulty). Scores range from 0 to 80, where higher scores indicate better lower limb function.

    Measured: Assessed at 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2026
  2. Study start11 Jun 2026
  3. Primary completion5 Dec 2030 (estimated)
  4. Study completion5 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants meeting the inclusion and exclusion criteria are centrally randomized in a 1:1 ratio intra-operatively, following stratification by longest gap length and nerve injured, and all nerve injuries qualifying for study enrollment shall be reconstructed with the same randomly assigned treatment.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
178 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07657182
Sponsor's protocol ID
ANG-CP-013
Acronym
Nerve-RESTORE℠
Status last verified
Oct 2026
First submitted
15 Jun 2026
Last updated
8 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Avance Nerve Graft and Sural nerve autograft in people with Peripheral Nerve Injury and Peripheral Nerve Discontinuity, run by Axogen Corporation at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Stacy Arnold ((386) 462-6800, clinicalresearch@axogeninc.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recovery of motor function (time frame: Assessed at 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07657182.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in